Seattle Genetics, Inc.

Seattle Genetics, Inc.

Seattle Genetics, Inc.

Overview
Date Founded

1998

Headquarters

21823 30th Drive SE,Bothell, WA 98021

Type of Company

Public

Employees (Worldwide)

1,302

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Contact Data
Trying to get in touch with decision makers at Seattle Genetics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Financial Officer & Chief Accounting Officer

General Counsel, Executive Vice President, Legal Affairs & Corporate Secretary

Chief Commercial Officer

Chief Technical Officer

Chief Medical Officer

Executive Vice President, Human Resources

Senior Vice President, Corporate Development

Senior Vice President, Program & Portfolio Management

Vice President, Chemistry & Senior Distinguished Fellow

Board of Directors

Co-Founder at Baker Bros. Advisors LP

Consultant at Aerie Pharmaceuticals, Inc.

Founder at Samsara Biocapital LLC

President, Chief Executive Officer & Director at Atreca, Inc.

Professional at Intercept Pharmaceuticals, Inc.

Chief Operating Officer at Vir Biotechnology, Inc.

Co-Founder at Ascenta Therapeutics, Inc.

Paths to Seattle Genetics, Inc.
Potential Connections via
Relationship Science
You
Seattle Genetics, Inc.
Owners & Shareholders
Details Hidden

BBA primarily invests client assets in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; ETFS; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Details Hidden

PRIMECAP invests primarily common stocks or securities with common stock characteristics, bonds and cash/cash equivalents. The firm utilizes fundamental research and bottom-up stock picking to construct portfolios. The main sources of information for research purposes include financial publications, inspections of corporate activities, research materials by others such as sell-side analysts, companies' annual reports and any related filings and press releases, meetings with executives of companies and their suppliers, competitors, customers, etc. All portfolios are built with the best ideas of each of the managers within the multi-manager investment process. PRIMECAP's investment strategy does not employ short sales or margin transactions, nor does it permit investments in derivatives or currency hedging. The firm follows an investment approach based on four key principles including commitment to fundamental research, long-term investment horizon, emphasis on individual decision-making and focus on value.

Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm's investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford's analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Recent Transactions
Details Hidden

Seattle Genetics, Inc. purchases Cascadian Therapeutics, Inc.

Details Hidden

Seattle Genetics, Inc. issued USD Common Stock

Details Hidden

Seattle Genetics, Inc. purchases Bristol Myers Squibb Co. /Monte Villa Parkway Research Center from Bristol-Myers Squibb Company

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onSeattle Genetics, Inc. issued USD Common Stock

Underwriter

Advised onSeattle Genetics, Inc. issued USD Common Stock

Underwriter

Advised onSeattle Genetics, Inc. issued Common Stock

Underwriter

Advised onSeattle Genetics, Inc. issued USD Common Stock

Legal Advisor

Advised onSeattle Genetics, Inc. issued USD Common Stock

Head, Healthcare Investment Banking

Advised onSeattle Genetics, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Partner at Cooley LLP

Clients

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Key Stats and Financials As of 2018
Market Capitalization
$10.9B
Total Enterprise Value
$8.52B
Earnings Per Share
$-1.41
Revenue
$655M
Three Year Compounded Annual Growth Rate Of Revenue
24.8%
Five Year Compounded Annual Growth Rate Of Revenue
19.45%
Total Equity
$1.27B
Net Profit
$-223M
EBITDAMargin
-35.74%
TEVNet Income
-38.27x
Debt TEV
0x
Enterprise Value Sales
13.02x
Total Debt
$0
EBITDA
$-234M
Investments
Details Hidden

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Investors
Details Hidden

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Details Hidden

Credit Agricole SA engages in the provision of banking and financial services. It operates through the following segments: French Retail Banking - Regional Banks, French Retail Banking - LCL, International Retail Banking, Savings Management & Insurance, Specialized Financial Services, Corporate & Investment Banking, and Corporate Centre. The French Retail Banking - Regional Banks segment provides banking and financial services for individual customers, farmers, small businesses, corporate and local authorities. The French Retail Banking - LCL segment offers asset management, insurance, and wealth management products. The International Retail Banking segment covers foreign subsidiaries and investments that are involved in retail banking. The Asset gathering segment offers: asset management activities; asset servicing for institutions; life insurance and personal insurance; property and casualty insurance; credit insurance activities; and private banking activities conducted mainly by CA Indosuez Private Banking and by Crédit Agricole subsidiaries. The Specialized Financial Services segment provides consumer financing services and specialized financial services such as factoring and leasing and this segment also handles the group subsidiaries which provides financial products and services to individual customers, small businesses, corporates and local authorities in France and abroad. The Large customers segment operates in capital markets, investment banking, and financing activities. The Corporate Center segment involves central body function, asset and liability management, and results of the private equity business and various companies of the group. The company was founded on November 5, 1894 and is headquartered in Montrouge, France.

Details Hidden

Entrepreneur in Residence at University of Washington

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

University of Miami Schools & Student Services | Coral Gables, FL

A private research university with more than 15,000 students from around the world, the University of Miami is a vibrant and diverse academic community focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. Led by President Donna E. Shalala, the University comprises 12 schools and colleges serving undergraduate and graduate students in more than 180 majors and programs. In 2012, U.S.News & World Report ranked UM No. 44 in its “Best Colleges” listings, the fourth year in a row it has been among the top 50, and it continued to be the highest ranked school in Florida. U.S. News also cited several of its programs in “America’s Best Graduate Schools.” Established in 1925 during the region’s famous real estate boom, UM is a major research university engaged in $360 million in research and sponsored program expenditures a year. While the majority of this work is housed at the Miller School of Medicine, investigators conduct dozens of studies in other areas, including marine science, engineering, education, and psychology

Senior Housing Properties Trust Real Estate Investment Trusts | Newton, MA

Senior Housing Properties Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Triple Net Leased Senior Living Communities, Managed Senior Living Communities, MOBs and All Other. The Triple Net Leased Senior Living Communities segment offers short and long term residential care and other services for residents, which the company receive rents from the operators. The Managed Senior Living Communities segment includes short and long term residential care and other services for residents, which the company pays fees to the operator to manage the communities for its account. The MOBs segment refers to the tenants paying for rent. The All Other segment comprises operations, including properties that offer wellness, fitness and spa services to members. The company was founded on December 16, 1998 and is headquartered in Newton, MA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Seattle Genetics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Seattle Genetics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Seattle Genetics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/seattle-genetics-inc-54751
  • https://relationshipscience.com/organization/seattle-genetics-inc-54751